Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...

A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the ...

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...

Number 4: Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, ...

Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...